What is Congenital Generalized Lipodystrophy

Congenital Generalized Lipodystrophy (CGL), also known as Berardinelli-Seip syndrome, is an extremely rare genetic disorder characterized by a near-total absence of body fat from birth or early infancy. This condition causes significant metabolic complications, including severe insulin resistance, high levels of fat in the blood, and an enlarged liver, as the body lacks the adipose tissue necessary to store energy properly.

What are the symptoms and body systems affected by Congenital Generalized Lipodystrophy?

Because individuals with Congenital Generalized Lipodystrophy lack subcutaneous fat, their muscles appear highly defined and veins are prominent. The primary systemic effects involve metabolic dysfunction, as the body struggles to process sugars and fats. Common clinical findings include:

• Severe hypertriglyceridemia (high blood fat levels)


• Insulin-resistant diabetes mellitus, often appearing in childhood


• Hepatomegaly (enlarged liver) due to excessive fat storage in the organ


• Accelerated bone growth and advanced bone age in early childhood


• Acanthosis nigricans (dark, velvety skin patches)

How is Congenital Generalized Lipodystrophy classified?

Congenital Generalized Lipodystrophy is divided into four main subtypes (CGL1 through CGL4) based on the specific gene mutation involved. While they all present with a lack of adipose tissue, they differ in their genetic origins: AGPAT2 (CGL1), BSCL2 (CGL2), CAV1 (CGL3), and PTRF (CGL4). CGL2 is often associated with more severe intellectual disability and cardiac issues compared to other types.

How rare is Congenital Generalized Lipodystrophy?

Congenital Generalized Lipodystrophy is a ultra-rare condition with an estimated prevalence of less than 1 in 1,000,000 people worldwide. It is inherited in an autosomal recessive pattern, meaning both parents must carry a copy of the mutated gene for a child to be affected. At DiseaseMaps.org, 4 community members have identified themselves as living with Congenital Generalized Lipodystrophy, highlighting the importance of global connection in such a rare patient population.

What differentiates this from other lipodystrophies?

Unlike acquired forms of lipodystrophy that develop later in life due to autoimmune issues or medications, Congenital Generalized Lipodystrophy is present from birth. It is distinguished from partial lipodystrophies by the near-total, rather than localized, loss of fat tissue.

Next steps

• Consult a pediatric endocrinologist for specialized metabolic management.


• Undergo genetic testing to identify the specific subtype of Congenital Generalized Lipodystrophy.


• Connect with the 4 other community members on DiseaseMaps.org to share management strategies.


• Monitor cardiovascular health regularly, as metabolic stress can impact heart function.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Berardinelli-Seip congenital lipodystrophy.


• Orphanet: Congenital generalized lipodystrophy (ORPHA: 791).


• OMIM (Online Mendelian Inheritance in Man): Entry #269700 (BSCL1).


• Lipodystrophy United: Resources for patients and families.